Annual Meeting Adjourned to Finalize Vote on Controversial Option Repricing Proposal
Summary
Coherus Oncology adjourned its Annual Meeting to May 29, 2026, to finalize the vote on a proposal to reprice 9.54 million underwater stock options, a move that could lead to substantial shareholder dilution.
Key Events
-
Annual Meeting Adjourned
The Annual Meeting, convened on May 27, 2026, was adjourned to reconvene on Friday, May 29, 2026, at 3:00 p.m. Pacific Time.
-
Vote on Option Repricing Pending
The adjournment is specifically to ensure all votes are counted for "Proposal No. 4 — Approval of the Reduction in the Exercise Price of Certain Outstanding Stock Options," a proposal previously highlighted as highly dilutive.
-
Repricing Mechanics Clarified
If Proposal No. 4 is approved, eligible options will be repriced to the closing trading price of common stock on May 29, 2026, and their term will be extended for 10 years from that date.
-
Conditional Repricing Terms
The repriced exercise price will revert to the original higher price if an option holder terminates service or exercises options prior to May 29, 2027.
Analysis
Coherus Oncology has adjourned its Annual Meeting to May 29, 2026, specifically to ensure all votes are counted for Proposal No. 4, which seeks shareholder approval to reprice 9.54 million underwater stock options. This adjournment suggests the vote on this highly dilutive proposal may be close or contentious. If approved, the options will be repriced to the closing stock price on May 29, 2026, and their term extended by 10 years, which could significantly increase future dilution for existing shareholders.
At the time of this filing, CHRS was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $256.1M. The 52-week trading range was $0.71 to $2.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.